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this article [1], it was noticed that some author correc-
tions were not included in the final article.
 Within the “Methods” section, the Cockcroft-Gault






Full lisCLcr mL=minð Þ ¼ 140 − ageð Þ
 weight kgð Þ = f72
 serum creatinine mg=dLð Þg
 0:85 if femaleð Þ
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Male, n(%) 123 (60.3)
Female , n(%) 81 (39.7)
Median CLcra, mL/min 88.7
NPb origin
Cancer related NP, n(%) 55 (27.0)
Chemotherapy related NP, n(%) 24 (11.7)
Non-cancer related NP, n(%) 125 (61.3)
Regular strong opioid




Median dosec (range), mg/day 60 (15–300)
no, n(%) 168 (82.4)
Initial dose of pregabalin
150 mg/day, n(%) 124 (60.8)
75 mg/day, n(%) 73 (35.8)
50 mg/day, n(%) 3 (1.5)
25 mg/day, n(%) 4 (1.9)
aCLcr: creatinine clearance using the Cockcroft-Gault equation
bNP: neuropathic pain
cconverted to oral morphine
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